T细胞中CD11a、CD49d和PSGL1三重敲低降低CAR-T细胞毒性,同时保留对小鼠实体瘤的活性
该研究在小鼠中证实,阻断LFA-1(CD11a/CD18)和VLA-4(CD49d/CD29)可降低CAR-T细胞的靶向脱肿瘤毒性。敲除CD11a和CD49d或敲低CD11a、CD49d及PSGL1的CAR-T细胞在体内毒性降低而不影响疗效,并促进记忆形成、减少强直信号。基于此构建人源低毒性CAR-T细胞,在体外和体内验证了可行性。
要点
- 阻断LFA-1和VLA-4可降低CAR-T细胞对表达靶抗原非恶性组织的靶向脱肿瘤毒性。
- 敲除CD11a和CD49d或敲低CD11a、CD49d及PSGL1的CAR-T细胞体内毒性降低且疗效不受影响。
- 该修饰促进T细胞记忆形成并减少强直信号,人源版本在体外和体内验证可行。
核心结论
- 靶向CD11a、CD49d和PSGL1可降低CAR-T细胞的靶向脱肿瘤毒性,同时保留抗实体瘤活性,为临床挑战提供潜在解决方案。
研究设计与样本
- 研究在小鼠中采用阻断抗体靶向LFA-1和VLA-4,并构建CD11a/CD49d双敲除或CD11a、CD49d及PSGL1三重敲低的CAR-T细胞。
- 进一步构建人源低毒性CAR-T细胞,并在体外和体内验证可行性。
主要发现
- 阻断LFA-1和VLA-4的抗体降低了CAR-T细胞在小鼠中的靶向脱肿瘤毒性。
- CD11a/CD49d双敲除或CD11a、CD49d及PSGL1三重敲低的CAR-T细胞在体内靶向脱肿瘤毒性降低,且不影响CAR-T细胞疗效。
- 上述修饰促进T细胞记忆形成并减少强直信号。
- 人源低毒性CAR-T细胞在体外和体内验证了可行性。
临床怎么用
- 原文未据此给出临床推荐。
局限性
- 原文未报告局限性。
以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。
原文
Chimeric antigen receptor (CAR)-T cell therapies have revolutionized the landscape of cancer treatment, in particular in the context of hematologic malignancies. However, for solid tumors that lack tumor-specific antigens, CAR-T cells can infiltrate and attack nonmalignant tissues expressing the CAR target antigen, leading to on-target, off-tumor toxicity. Severe on-target, off-tumor toxicities have been observed in clinical trials of CAR-T therapy for solid tumors, highlighting the need to address this issue. Here, we demonstrated that targeting the cell adhesion and migration molecules lymphocyte function-associated antigen 1 (LFA-1; CD11a/CD18) and very late activation antigen 4 (VLA-4; CD49d/CD29) with blocking antibodies reduced the on-target, off-tumor toxicity of CAR-T cells in mice. To translate this observation into improved CAR-T cell therapy, we either knocked out both CD11a and CD49d or knocked down CD11a and CD49d along with PSGL1, another cell adhesion molecule, in CAR-T cells. We found that these modified CAR-T cells exhibited reduced on-target, off-tumor toxicity in vivo without affecting CAR-T cell efficacy. Furthermore, we showed that this approach promoted T cell memory formation and decreased tonic signaling. On the basis of these data, we engineered a human version of these low-toxicity CAR-T cells and further validated the feasibility of this approach in vitro and in vivo. Together, these results provide a potential solution to address the clinical challenge of on-target, off-tumor toxicity in CAR-T therapy.
引用
- Wang H, Wu Z, Cui D, et al. Triple knockdown of CD11a, CD49d, and PSGL1 in T cells reduces CAR-T cell toxicity but preserves activity against solid tumors in mice. Sci Transl Med. 2025. PMID: 39841806. doi:10.1126/scitranslmed.adl6432
供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。